# Trade Mark Journal No.2026/004 23 January 2026

## WO0000001894506 (5,10)

Office of origin: European Union Intellectual Property Office (EUIPO)

Date of International Registration:30 October 2025
Date of designation in the UK: 30 October 2025

The mark contains the colours purple and yellow.

International priority date claimed: 6 May 2025 (European Union Intellectual Property Office (EUIPO)) (019182904)

Class 5
  Pharmaceutical and biopharmaceutical products and preparations for the medical treatment of gastrointestinal diseases and disorders emanating from microbiota dysfunction; pharmaceutical and biopharmaceutical products and preparations used for the treatment of cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; pharmaceuticals used to maintain health or restore health to a human subject in the field of treatment of a disturbed microbial community, namely, for the treatment of dysbiosis, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; biological preparations in the nature of microorganisms used to maintain health or restore health to a human subject in the field of treatment of a disturbed microbial community, namely, for the treatment of dysbiosis, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases.
Class 10
  Medical and surgical apparatus and instruments; drug delivery devices, including medical apparatus and instruments for administration of pharmaceutical and biopharmaceutical products and preparations; drug delivery devices to treat gut microbiome-related disorders, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; drug delivery devices to treat gut microbiome-related disorders, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, in the nature of a kit comprising a prefilled suspension bag and administration tube set.

MAAT PHARMA

Representative: ICOSA, 83 Avenue Denfert-Rochereau, F-75014 PARIS, FRANCE